We are live on ! Find out more
OCRX

Ocera Therapeutics
OCRX

Delisted

OCRX was delisted on the 8th of December, 2017.

33 hedge funds and large institutions have $22.9M invested in Ocera Therapeutics in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

77% more capital inflows, than outflows

Capital inflows: $3.6M | Capital outflows: $2.03M

14% more funds holding

Funds holding: 29 → 33 (+4)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

Holders
33
Holders Change
+4
Holders Change %
+13.79%
% of All Funds
0.88%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
6
Reduced
10
Closed
2
Calls
$114​K
Puts
–
Net Calls
+$114​K
Net Calls Change
+$64​K

OCRX Hedge Fund Activity: Q1 2016 in Review

33 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in Ocera Therapeutics (OCRX) for Q1 2016, worth a combined $22.9M — up 2.2% from $22.4M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new OCRX positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was VHCP Management II, opening a new position worth an estimated $2.71M. The largest seller was Sphera Funds Management, cutting an estimated $1.04M.

  • 33 institutional investors held Ocera Therapeutics (OCRX) as of Q1 2016, up from 29 in Q4 2015.
  • Funds reported $22.9M of Ocera Therapeutics stock for Q1 2016, up 2.2% quarter-over-quarter.
  • 5 funds opened new Ocera Therapeutics positions in Q1 2016 and 2 closed out, a net change of +3 holders.
  • The largest Ocera Therapeutics buyer in Q1 2016 was VHCP Management II, an estimated $2.71M added.
  • The largest Ocera Therapeutics seller in Q1 2016 was Sphera Funds Management, an estimated $1.04M sold.

Based on aggregated 13F filings for Q1 2016.